NeoImmuneTech, Inc. (KOSDAQ:950220)
1,410.00
-75.00 (-5.05%)
Nov 20, 2026, 3:30 PM KST
NeoImmuneTech Revenue
NeoImmuneTech had revenue of 4.88B KRW in the quarter ending September 30, 2026, with 26,541.51% growth. This brings the company's total for the last twelve months to 6.60B, up 6,902.30% year-over-year. In the year 2025, NeoImmuneTech had annual revenue of 94.82M, down -44.35%. That makes NeoImmuneTech the 40,110th largest company in the world by revenue and 2,491st in South Korea.
Revenue (ttm)
6.60B
Revenue Growth
+6,902.30%
P/S Ratio
21.11
Revenue / Employee
126.97M
Employees
42
Market Cap
139.40B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 94.82M | -75.56M | -44.35% |
| Dec 31, 2024 | 170.38M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bioneer | 345.88B |
| GC Cell | 162.00B |
| HLB Therapeutics | 64.45B |
| GC Genome | 32.64B |
| Anterogen.Co.,Ltd. | 9.29B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |
| MedPacto | 4.80B |
NeoImmuneTech News
- 11 days ago - NeoImmuneTech Quarterly report: Q3 2026 - Filings
- 3 months ago - NeoImmuneTech Quarterly report: Q2 2026 - Filings